Lancashire and South Cumbria
Formulary
Formulary
13 Skin
This chapter of the formulary is under continual development, please let the team know if you have any comments about the contents: mlcsu.lscformulary@nhs.net.
For more information about the formulary development process, please see: https://www.lancsmmg.nhs.uk/lancashire-and-south-cumbria-icb-formulary-development/
13-06-01 Benzoyl peroxide and azelaic acid
Links
LSCMMG: Gastroenterology Biologics Pathway- LSCMMG: Primary Care Constipation Guidelines
- MHRA Drug Safety Update June 2017: Brimonidine gel (Mirvaso): risk of systemic cardiovascular effects; not to be applied to damaged skin
- MHRA Drug Safety update Nov 2016: Brimonidine gel (Mirvaso): risk of exacerbation of rosacea
- MHRA: Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review
- NICE CG147: Diverticular disease: diagnosis and management
- NICE CG184 Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management
- NICE CG61: Irritable bowel syndrome in adults: diagnosis and management
- NICE new medicine summary: Inflammatory lesions of papulopustular rosacea: ivermectin 10 mg/g cream
- NICE NG1: Gastro-oesophageal reflux disease: recognition, diagnosis and management in children and young people
- NICE NG198: Acne vulgaris: management
- NICE: Inflammatory lesions of papulopustular rosacea: ivermectin 10 mg/g cream